3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neutropenia
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Carcinoma, Non-Small-Cell Lung
1
Burkitt Lymphoma
1
Interventions
Carboplatin
103
Pemetrexed
96
pembrolizumab
78
Docetaxel
78
Cisplatin
72
Paclitaxel
70
Erlotinib Hydrochloride
50
Gemcitabine
48
Radiotherapy
42
Nivolumab
35
Bevacizumab
35
atezolizumab
24
Radiosurgery
24
durvalumab
19
Cyclophosphamide
17
130-nm albumin-bound paclitaxel
15
Vinorelbine
14
Taxes
14
Radiation
14
Etoposide
13
Ipilimumab
12
Albumin-Bound Paclitaxel
12
avelumab
11
Drug Therapy
10
Cetuximab
10
spartalizumab
9
Sorafenib
9
trametinib
8
osimertinib
8
capmatinib
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Carcinoma, Non-Small-Cell Lung
×
flt3 ligand protein
×
Clear all
NCT04491084
2024-02-28
FLT3
Albert Einstein College of Medicine
Phase 1/2
Terminated
5 enrolled
8 charts